GSK
GlaxoSmithKline PLC ADR
NYSE: GSK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$50.95
+1.47% today
Updated 2026-06-03
Market cap
$104.69B
P/E ratio
13.71
P/S ratio
3.19x
EPS (TTM)
$3.81
Dividend yield
3.45%
52W range
$34 – $61
Volume
4.0M
WallStSmart proprietary scores
58
out of 100
Grade: C+
Hold
Investment rating
4.7
Growth
C4.5
Quality
C8.5
Profitability
A4.0
Valuation
C6/9
Piotroski F-Score
Moderate
1.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$56,870.00
+111519.23%
12-Month target
$67.43
+32.35%
Intrinsic (DCF)
$46.24
Margin of safety
-26.49%
1 Strong Buy1 Buy5 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 24.76% — strong efficiency
+ Free cash flow $698.00M — positive
Risks
- Altman Z 1.34 — distress zone
- 26.49% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $29.32B | $30.33B | $31.38B | $32.67B | $32.78B | $47.8B |
| Net income | $14.96B | $4.93B | $2.58B | $5.72B | $1.74B | — |
| EPS | — | — | — | — | $3.81 | $2.57 |
| Free cash flow | $5.14B | $6.26B | $3.57B | $5.82B | $698.00M | — |
| Profit margin | 51.00% | 16.25% | 8.21% | 17.50% | 17.80% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-11 | GSK, PLC | Buy | 1,470,000 | $19.00 |
| 2024-09-27 | GSK, PLC | Buy | 2,791,930 | $8.00 |
| 2023-12-07 | GSK, PLC | Buy | 3,300,000 | $5.00 |
Peer comparison
Smart narrative
GlaxoSmithKline PLC ADR trades at $50.95. representing a P/E of 13.71x trailing earnings. Our Smart Value Score of 58/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.34, it sits in the distress. TTM revenue stands at $32.78B. with profit margins at 17.80%. Our DCF model estimates intrinsic value at $46.24.
Frequently asked questions
What is GlaxoSmithKline PLC ADR's stock price?
GlaxoSmithKline PLC ADR (GSK) trades at $50.95, on a P/E of 13.7x and a P/S of 3.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is GlaxoSmithKline PLC ADR overvalued?
GlaxoSmithKline PLC ADR carries a Smart Value Score of 58/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $46.24 against the $50.95 price, so on cash flow terms the market is paying a premium for GlaxoSmithKline PLC ADR's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of GlaxoSmithKline PLC ADR (GSK)?
The 12-month analyst consensus target is $56,870.00, about 111519.2% above the current $50.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of GSK by 2030?
Our research-backed model puts the 2030 base case at $362.82, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of GlaxoSmithKline PLC ADR (GSK)?
Our DCF model estimates intrinsic value at $46.24, a -26.5% margin of safety versus today's $50.95. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is GlaxoSmithKline PLC ADR's revenue?
GlaxoSmithKline PLC ADR's trailing twelve-month revenue is $32.78B, and our model projects it reaching about $60.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
GlaxoSmithKline PLC ADR's Altman Z-Score is 1.34, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.19x
ROE24.76%
Beta0.29
50D MA$52.95
200D MA$49.90
Shares out2.00B
Float1.95B
Short ratio—
Avg volume4.0M
Performance
1 week+0.00%
1 month-3.51%
3 months-4.09%
YTD+1.39%
1 year—
3 years—
5 years—